[Immunomodulatory treatment with beta-interferon in patients with cervical intraepithelial neoplasia and human papillomavirus infection: long-term follow-up]

Rev Esp Quimioter. 2005 Mar;18(1):26-31.
[Article in Spanish]

Abstract

The aim of this study was to evaluate the long-term efficacy of beta-interferon treatment in the management of cervical intraepithelial neoplasia associated with human papillomavirus (HPV) infection in a selected group of patients. Thirty-nine patients who had histologically proven cervical intraepithelial neoplasia I or II with concurrent HPV infection were administered 27,000,000 IU of intramuscular beta-interferon. Periodical controls were carried out based on Papanicolaou smears and/or colposcopic examination and DNA HPV determination was performed by hybridation test, for a maximum of 8 years' follow-up. An initial complete response rate of 75% was obtained, with a recurrence rate of 25%, cervical intraepithelial neoplasia with late manifestation was of higher grade. Treatment interruption due to side-effects was not necessary. Associated viral infections appeared to be a recurrence risk factor, but not smoking or parity. While immunomodulatory treatment with beta-interferon has good long-term results in cervical intraepithelial neoplasia I/II treatment, wider randomized studies are required to obtain conclusive results.

Publication types

  • English Abstract

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon-beta / therapeutic use*
  • Middle Aged
  • Papillomavirus Infections / complications*
  • Papillomavirus Infections / drug therapy*
  • Time Factors
  • Uterine Cervical Diseases / complications*
  • Uterine Cervical Diseases / drug therapy*
  • Uterine Cervical Dysplasia / complications*
  • Uterine Cervical Dysplasia / drug therapy*
  • Uterine Cervical Neoplasms / complications*
  • Uterine Cervical Neoplasms / drug therapy*

Substances

  • Adjuvants, Immunologic
  • Interferon-beta